Indocid Retard

Indometacin, the active ingredient in Indocid Retard, is a nonsteroidal anti‑inflammatory drug (NSAID) presented as an oral dosage form for oral use. It is employed to relieve pain and inflammation in conditions such as rheumatoid arthritis, osteoarthritis, gout flares, ankylosing spondylitis and other acute inflammatory disorders.

GNH USA supplies Indocid Retard as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution. Clients benefit from consistent product availability and regulatory support.

Indocid Retard (indometacin) acts on inflammatory pathways associated with musculoskeletal and crystal‑induced arthropathies. - Rheumatoid arthritis: reduces joint inflammation and pain in adult patients. - Osteoarthritis: alleviates chronic joint discomfort and swelling. - Gout flares: provides rapid relief of acute gouty arthritis symptoms. - Ankylosing spondylitis: diminishes spinal inflammation and improves mobility. - Acute pain and inflammation: controls short‑term pain from various inflammatory conditions.

Indocid Retard may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Gastrointestinal discomfort: nausea, dyspepsia or abdominal pain. - Headache: mild to moderate intensity. - Dizziness or vertigo: transient sensations of imbalance. - Skin rash: mild erythema or pruritus. - Elevated liver enzymes: mild, reversible changes in hepatic function tests.

Serious or Rare Side Effects: - Gastrointestinal ulcer or bleeding: potentially life‑threatening hemorrhage. - Reninal impairment: acute kidney injury or reduced renal function. - Severe hepatic injury: hepatitis or liver failure. - Blood dyscrasias: agranulocytosis, thrombocytopenia or anemia. - Life‑threatening skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Anaphylaxis: acute allergic reaction with airway compromise.

Before prescribing Indocid Retard, clinicians should evaluate patient risk factors and monitor therapy closely. - Assess renal function: check baseline creatinine and eGFR, especially in the elderly. - Monitor hepatic enzymes: perform liver function tests periodically during treatment. - Use lowest effective dose: limit duration to the shortest period necessary to control symptoms. - Avoid in known hypersensitivity: discontinue if allergic reactions such as rash or bronchospasm occur. - Caution in cardiovascular disease: consider increased risk of thrombotic events with long‑term NSAID use. - Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Indocid Retard can interact with several medicines, altering efficacy or safety.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): increased risk of serious bleeding. - Lithium: heightened lithium serum concentrations and toxicity. - Methotrexate: reduced clearance leading to potential toxicity. - ACE inhibitors or diuretics: possible decline in renal function. - SSRIs or other serotonergic agents: amplified bleeding tendency.

Moderate Interactions (Monitor Closely): - Other NSAIDs or COX‑2 inhibitors: additive gastrointestinal toxicity. - Corticosteroids: increased risk of ulceration and bleeding. - Antihypertensives (e.g., beta‑blockers): may diminish blood pressure control. - Cyclosporine: enhanced nephrotoxic effect. - Oral hypoglycemics: potential alteration of glucose control.